Empagliflozin Cuts Brain Injury After Cardiac Arrest 02/22/26

Welcome to Cardiology Today – Recorded February 22, 2026. This episode summarizes 5 key cardiology studies on topics like hypotension and Coronary embolism. Key takeaway: Empagliflozin Cuts Brain Injury After Cardiac Arrest. Article Links: Article 1: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. (European heart journal) Article 2: Three-dimensional echocardiography for valvular heart disease: clinical implications. (European heart journal) Article 3: Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock. (Circulation. Heart failure) Article 4: Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study. (Journal of the American Heart Association) Article 5: Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats. (Journal of the American Heart Association) Full episode page: https://podcast.explainheart.com/podcast/empagliflozin-cuts-brain-injury-after-cardiac-arrest-02-22-26/ Featured Articles Article 1: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41721795 Summary: Lipoprotein apheresis (L. A.) is the only approved treatment for patients with elevated lipoprotein(a). The Lp(a)FRONTIERS APHERESIS trial established a treatment protocol where adult patients with lipoprotein(a) levels greater than 60 milligrams per deciliter and established cardiovascular disease were randomized. These patients had previously undergone frequent lipoprotein apheresis sessions. Participants received either 80 milligrams of pelacarsen or placebo every 4 weeks for 52 weeks, continuing weekly lipoprotein apheresis sessions. Article 2: Three-dimensional echocardiography for valvular heart disease: clinical implications. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41721505 Summary: Three-dimensional echocardiography has emerged as an essential tool in evaluating and managing valvular heart disease. This imaging modality offers superior accuracy and detailed visualization when used with both transthoracic and transesophageal approaches. Its importance has been particularly underscored in guiding transcatheter valve interventions for high-risk or inoperable patients. The technology enables precise assessment of valvular anatomy, directly improving patient management. Article 3: Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock. Journal: Circulation. Heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41711037 Summary: This study evaluated adult patients with Society for Cardiovascular Angiography and Interventions (S. C. A. I.) stage B cardiogenic shock from 2017 to 2022 across a six-hospital system. The definition for S. C. A. I. B cardiogenic shock included hypotension, specifically systolic blood pressure less than or equal to 90 mmHg or mean blood pressure less than or equal to 65 mmHg, or hypoperfusion indicated by lactate levels between 2 to 5 milliequivalents per liter. Cardiac arrest, use of circulatory support, and noncardiac etiologies were explicitly excluded from this definition. This framework provides a basis for understanding and studying this patient population. Article 4: Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study. Journal: Journal of the American Heart Association PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717963 Summary: This multicenter study included 489 patients diagnosed with coronary embolism across 10 hospitals, using Shibata criteria for diagnosis. The study found that 241 patients, representing 49 percent of the cohort, had atrial fibrillation-related coronary embolism. Researchers identified distinct characteristics between atrial fibrillation-related and non-atrial fibrillation coronary embolism patient groups. This research provides initial comparative data on this underrecognized cause of acute myocardial infarction. Article 5: Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats. Journal: Journal of the American Heart Association PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41717961 Summary: This study demonstrated that empagliflozin attenuates global cerebral ischemic injury following cardiac arrest in rats. The observed neuroprotective effects were achieved through the enhancement of ketone body oxidative metabolism. Researchers utilized a model where 206 adult male Sprague-Dawley rats were subjected to cardiac arrest via ventricular fibrillation and subsequent cardiopulmonary resuscitation. This finding positions empagliflozin as a potential therapeutic agent for reducing neurological deficits after cardiac arrest. Transcript Today’s date is February 22, 2026. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Lipoprotein apheresis (L. A.) is the only approved treatment for patients with elevated lipoprotein(a). The Lp(a)FRONTIERS APHERESIS trial established a treatment protocol where adult patients with lipoprotein(a) levels greater than 60 milligrams per deciliter and established cardiovascular disease were randomized. These patients had previously undergone frequent lipoprotein apheresis sessions. Participants received either 80 milligrams of pelacarsen or placebo every 4 weeks for 52 weeks, continuing weekly lipoprotein apheresis sessions. Article number two. Three-dimensional echocardiography for valvular heart disease: clinical implications. Three-dimensional echocardiography has emerged as an essential tool in evaluating and managing valvular heart disease. This imaging modality offers superior accuracy and detailed visualization when used with both transthoracic and transesophageal approaches. Its importance has been particularly underscored in guiding transcatheter valve interventions for high-risk or inoperable patients. The technology enables precise assessment of valvular anatomy, directly improving patient management. Article number three. Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock. This study evaluated adult patients with Society for Cardiovascular Angiography and Interventions (S. C. A. I.) stage B cardiogenic shock from 2017 to 2022 across a six-hospital system. The definition for S. C. A. I. B cardiogenic shock included hypotension, specifically systolic blood pressure less than or equal to 90 mmHg or mean blood pressure less than or equal to 65 mmHg, or hypoperfusion indicated by lactate levels between 2 to 5 milliequivalents per liter. Cardiac arrest, use of circulatory support, and noncardiac etiologies were explicitly excluded from this definition. This framework provides a basis for understanding and studying this patient population. Article number four. Atrial Fibrillation Versus Nonatrial Fibrillation Coronary Embolism: A Multicenter Study. This multicenter study included 489 patients diagnosed with coronary embolism across 10 hospitals, using Shibata criteria for diagnosis. The study found that 241 patients, representing 49 percent of the cohort, had atrial fibrillation-related coronary embolism. Researchers identified distinct characteristics between atrial fibrillation-related and non-atrial fibrillation coronary embolism patient groups. This research provides initial comparative data on this underrecognized cause of acute myocardial infarction. Article number five. Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats. This study demonstrated that empagliflozin attenuates global cerebral ischemic injury following cardiac arrest in rats. The observed neuroprotective effects were achieved through the enhancement of ketone body oxidative metabolism. Researchers utilized a model where 206 adult male Sprague-Dawley rats were subjected to cardiac arrest via ventricular fibrillation and subsequent cardiopulmonary resuscitation. This finding positions empagliflozin as a potential therapeutic agent for reducing neurological deficits after cardiac arrest. Thank you for listening. Don’t forget to subscribe. Keywords hypotension, Coronary embolism, transcatheter valve interventions, hypoperfusion, lactate, Shibata criteria, lipoprotein(a), cardiac arrest, atrial fibrillation, secondary prevention, lipoprotein(a) apheresis, ketone body metabolism, transthoracic echocardiography, cardiovascular disease, acute myocardial infarction, transesophageal echocardiography, Society for Cardiovascular Angiography and Interventions, Pelacarsen, Cardiogenic shock, Empagliflozin, cerebral ischemic injury, Three-dimensional echocardiography, neuroprotection, valvular heart disease. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Empagliflozin Cuts Brain Injury After Cardiac Arrest 02/22/26 first appeared on Cardiology Today.